Treatment of Community-Acquired Pneumonia in Adults

Introduction to Recommended Therapies

The American College of Physicians and the Infectious Diseases Society of America recommend against using cotrimoxazole as first-line therapy for community-acquired pneumonia in adults due to inadequate activity against penicillin-resistant Streptococcus pneumoniae 1, 2
The French and IDSA guidelines specifically exclude cotrimoxazole from community-acquired pneumonia treatment algorithms due to poor activity against penicillin-resistant S. pneumoniae, the most common bacterial cause of pneumonia 1, 2

Only 78.1% of H. influenzae isolates show susceptibility to TMP-SMX, with even lower activity against other common respiratory pathogens like K. pneumoniae 2
Cotrimoxazole provides no coverage for atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella) that cause a significant proportion of community-acquired pneumonia 3

Amoxicillin 3 g/day is the reference standard for community-acquired pneumonia in adults without risk factors 1, 2
For hospitalized non-severe pneumonia, Beta-lactam (ceftriaxone 1-2 g IV daily) plus macrolide (azithromycin 500 mg IV/PO daily) provides comprehensive coverage 3
For severe pneumonia requiring hospitalization, Broad-spectrum β-lactamase stable antibiotic plus macrolide is recommended 1
Alternative monotherapy, Respiratory fluoroquinolones (levofloxacin 750 mg or moxifloxacin 400 mg daily) provide broad-spectrum coverage including atypicals 3

Never use TMP-SMX as empiric therapy for serious pneumonia without culture and susceptibility data, as resistance rates are too high to ensure adequate coverage 2
Reassess treatment within 48-72 hours, if no clinical improvement occurs, switch to guideline-recommended agents rather than continuing inadequate therapy 1, 2
In resource-limited settings, historical data from pediatric studies showed cotrimoxazole had higher failure rates than amoxicillin for pneumonia (19% vs 16% in non-severe cases, 33% vs 18% in severe cases) 4, 5